Product Launch (Blog)

Jul, 06 2023

Improving Patient Experience and Reducing Mortality

 

The malaria treatment market offers a diverse range of medication categories to combat the deadly infectious disease caused by the Plasmodium parasite. Patients can access various treatment choices with options such as primaquine, mefloquine, quinine, chloroquine, and more. This wide range of malaria treatment products improves patient experience and reduces the risk of mortality. The market analysis highlights the importance of treatment options and their impact on patient outcomes.

According to Data Bridge Market Research, the Malaria Treatment Market accounted for CAGR of malaria treatment market is tend to be around 6.6% in the mentioned forecast period. The market value is USD 647.13 million in 2022, and it would grow up to USD 1079.07 million by 2030.

“Rising frequency of malaria”

The rising prevalence of malaria in the Asia-Pacific region is a significant driver for the growth of the malaria treatment market. Countries like India, Indonesia, Pakistan, Myanmar, and Papua New Guinea have a high incidence of malaria, with millions of cases reported yearly. Moreover, over 80% of the population in malaria-prone countries in the region is at an increased risk of contracting the disease. Additionally, the increasing number of travelers visiting malaria-affected areas contributes to the demand for malaria treatment, further boosting the market's growth.

What restraints the growth of malaria treatment market?

“Rising quality issues of drugs”

The market for malaria drugs faces challenges related to drug quality issues. Many manufacturers fail to obtain WHO prequalification for producing malaria treatment drugs, resulting in substandard quality drugs in the market. These quality issues hinder the market's growth as they compromise the effectiveness and safety of the drugs, leading to concerns regarding their efficacy in treating malaria.

Segmentation:  Malaria Treatment Market

The malaria treatment market is segmented on the basis of agent, type, treatment type, route of administration, distribution channel and end-user. 

  • On the basis of agent, the malaria treatment market is segmented into plasmodium falciparum, p. vivax, p. ovale, p. malariae and p. knowlelsi
  • On the basis of type, the malaria treatment market is segmented into medication and vaccination.
  • On the basis of treatment type, the malaria treatment market is segmented into suppressive treatment and radical treatment.
  • On the basis of drug type, the malaria treatment market is segmented into branded and generics.
  • On the basis of route of administration, the malaria treatment market is segmented into oral and parenteral.
  • On the basis of end user, the malaria treatment market is segmented into hospitals, specialty clinics, diagnostic centers and others.
  • On the basis of distribution channel, the malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies and online pharmacies.

Regional Insights: North America Dominates the Malaria Treatment Market

In North America, the dominance in the market can be attributed to the high occurrence of malaria vector-borne disease. The regional governments' increased funding for healthcare, coupled with advancements in clinical developments and frequent product launches, are fueling market growth. These factors contribute to improved treatment options and better disease management strategies.

Asia-Pacific is experiencing rapid growth in the malaria treatment market due to increasing healthcare expenditure and rising awareness about the symptoms of malaria, a vector-borne disease. The region's proactive approach towards healthcare and growing emphasis on disease management drive the demand for effective malaria treatments.

To know more about the study visit, https://www.databridgemarketresearch.com/ru/reports/global-malaria-treatment-market

Recent Developments in Malaria Treatment Market

  • In 2021, Zydus Cadila collaborated with Medicines for Malaria Venture to develop ZY19489, an antimalarial drug. The U.S. FDA approved the drug, which showed promising results in Phase I trials, demonstrating a long half-life and the potential for a single-dose cure for malaria. In separate malaria challenge trials, ZY19489 displayed potent antimalarial activity following a single-dose oral administration, highlighting its effectiveness in combating the disease.

The Prominent Key Players Operating in the Malaria Treatment Market Include:

  • Actiza Pharmaceutical Private Limited (India)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Cipla Inc. (India)
  • Lupin (India)
  • Ipca Laboratories Ltd (India)
  • Mylan N.V. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Zydus Group (India)
  • MMV (Switzerland)
  • Novartis AG (Switzerland)
  • Sumaya Biotech (Germany)
  • Taj Pharmaceuticals Limited (India)
  • OSIVAX (France)
  • Strides Pharma Science Limited (India)

Above are the key players covered in the report, to know about more and exhaustive list of  malaria treatment market  companies contact, https://www.databridgemarketresearch.com/ru/contact

Research Methodology: Global Malaria Treatment Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

 


Client Testimonials